Fresenius Group Overview

07.04.2017

DGAP Ad-hoc - Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms discussions with Akorn, Inc.

  • Contact

    Markus Georgi

    Senior Vice President Investor Relations
    T: +49 (0) 6172 608-2485
    markus.georgi@fresenius.com

Fresenius SE & Co. KGaA: Fresenius SE & Co. KGaA confirms discussions with Akorn, Inc.

Fresenius SE & Co. KGaA / Key word(s): Mergers & Acquisitions

07-Apr-2017 / 22:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Fresenius SE & Co. KGaA confirms that Fresenius Kabi is currently in discussions with Akorn, Inc., a US specialty generic pharmaceutical company, concerning a potential acquisition of Akorn, Inc. Akorn, Inc. shares are listed on the NASDAQ Global Select Market.

Entry into a formal agreement of a transaction remains subject to, among other things, approval by the Executive Board and Supervisory Board of Fresenius Management SE and the board of directors of Akorn, Inc. There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction. Neither Fresenius SE & Co. KGaA nor Akorn, Inc. intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so, or a formal agreement has been reached.

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE

The Executive Board

Bad Homburg v.d.H., 7 April 2017

Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com

End of note


07-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this